Innovodigm, a medtech startup focused on needle-free vaccine delivery, has raised Rs 5.5 crore in a seed funding round. The round was led by the Indian Angel Network (IAN), which contributed Rs 4.5 crore, with additional backing from PadUp Ventures.
The newly raised capital will be used to streamline the company’s processes, build out infrastructure, and grow its team. Innovodigm is preparing for third-party preclinical validation and aims to begin clinical trials in the near future.
New Way to Vaccinate
Founded in 2020 by Jhimli Manna and Ayan Chatterjee, Innovodigm is creating a Microneedle Array Patch (MAP) platform. This needle-free system delivers vaccines through a painless patch rather than traditional injections. The company’s technology keeps vaccines stable for up to 120 days at temperatures as high as 40°C, removing the need for costly cold storage.
This innovation could be a game-changer, especially in rural and underserved areas where traditional vaccines face storage and transportation challenges. By reducing the need for syringes and cold-chain logistics, Innovodigm’s solution can also cut down on medical waste and simplify distribution.
Recognition and Partnerships
Innovodigm’s work has already gained recognition. Its MAP technology was named one of the Top 2 Technologies at the Nano Electronics Showcase 2025 hosted by the Ministry of Electronics and IT. The company has also signed a Material Transfer Agreement with an Indian vaccine manufacturer to begin third-party testing. Clinical trials are expected to start in 2026.
The startup is a spinout from IIT Kharagpur’s Microelectronics and MEMS Lab and operates at the intersection of medical science and public health. Its focus is on scalable, affordable immunization solutions suitable for both the Indian and global markets.
Future Plans in Place
Innovodigm plans to expand its patch technology to support vaccines for diseases like measles, hepatitis, influenza, and COVID-19 boosters. The company also wants to build decentralized manufacturing hubs in low- and middle-income countries to shorten supply chains and reduce distribution delays.
By making vaccines more accessible and easier to distribute, Innovodigm hopes to reshape how the world handles immunization, making it faster, safer, and more efficient for everyone.
